BetaGlue Therapeutics’ Post

Panakes Partners’ portfolio company BetaGlue Technologies has announced the 6m€ investment by ENEA Tech e Biomedical bringing the total amount to 24m€. https://lnkd.in/dskZRtQn Congrats to Colin Story and the BetaGlue Technologies team !

Superior technology for the most challenging cancers. Congrats BetaGlue Therapeutics on this investment. In the future, we will support such promising therapy methods with #imaging #technology designed for interventional oncology. For precise and safe therapies aimed at achieving the best possible outcome. #InterventionalOncology #FutureOfMedicine

The new PMOD 4.5 includes advanced tools for translational oncology research, such as dynamic segmentation tools for changing tumor volumes and organ positions, image registration across acquisitions, and detailed metadata control in the Metadata Explorer. Learn more: https://lnkd.in/dYbJiTms #Bruker #PreclinicalImaging #Imaging #PMOD #Oncology

🧐 Why ARCTis™ Cryopreserved Tumors?.... 🤩 InSphero’s Answer to Oncology Research Needs! In this video, Dr. Jan Lichtenberg, CEO and Co-Founder of InSphero, shares the inspiration behind the development of our ARCTis™ #Cryopreserved #Tumor Models. 🦾 Addressing the pressing challenges faced by researchers in #oncology, ARCTis™ was created to provide a reliable, ready-to-use solution for advancing drug discovery and personalized medicine. 👀 Learn how this innovative product unlocks the potential of 3D in vitro technology to accelerate cancer research. Want to learn more? Discover ARCTis™ Cryo Tumors via the link in comments 👇 Nils Goedecke, Olivier Frey, Tala Issa, Simon Stroebel, PhD, Simon Hutter, Paul Edgard Clémençon, Bärbel Ulmer, Christine Schwenk, Arumugham (Ragoo) Raghunathan, Arnab China, Ph.D., Sue Grepper, PhD, Rositsa Hadzhipetrova, Tina Žel #3DCellCulture #PreClinicalTesting #CancerResearch #TumorModel #Cryopreservation #Biotech #InSphero #TheModelofExcellence™ #interview

Great read on the transformative potential of highly multiplexed tissue imaging (HMTI) in precision oncology. The recent Cancer Discovery review underscores its role in analyzing complex tumor ecosystems and advancing biomarker discovery. As HMTI gains traction in clinical settings, the integration of AI-driven multiplex analysis tools becomes increasingly essential. Leveraging such technologies can provide actionable spatial insights that predict therapy responses and inform treatment decisions, thereby accelerating biomarker discovery and advancing precision medicine. https://hubs.li/Q02XNxqJ0 #Biomarkers #SpatialBiomarkers #PrecisionOncology #Multiplex #mIF #DigitalPathology #AIPathology

Growth form of #ColonCancer liver metastases may influence response to immunotherapy. 🤝 Led by David G. Molleví, head of the Tumor and Stromal Chemoresistance research group at Bellvitge Biomedical Research Institute - IDIBELL and Institut Català d'Oncologia (ICO), in collaboration with Artur Mezheyeuski, researcher of the #VHIO’s molecular Oncology group & Uppsala University. ➡️ https://lnkd.in/dNG3VQTK #VHIO #CancerResearch #Oncology

Read our interview with bioengineer Matthew Ishahak, PhD, from WashU about his new organoid model for studying glioblastoma tumorigenesis, and his perspective on how #spatialtranscriptomics will transform cancer drug discovery: https://bit.ly/3zrJnYV

What a fantastic article by Natalya Ortolano interviewing bioengineer Matthew Ishahak, a postdoctoral research scholar in the lab for Dr. Jeffrey Millman at the Washington University School of Medicine in St. Louis! Matt used 10x Genomics "single cell sequencing (#Chromium #SingleCell Gene Expression) and single cell #spatial transcriptomics (#Xenium #InSitu) to see that  engineered #glioblastoma brain organoids (eGBOs) displayed expected differences in cell state and spatial architecture based on the initial mutation. As far as the greater impact of the research, in Matt's words, "As we start to have a deeper understanding of the altered gene expression and spatial organization of these diseases using engineered models like eGBOs, that will provide another readout for drug screening. Having those additional readouts can only improve drug discovery" Xenium work was done through The McDonnell Genome Institute, WashU Medicine. References: Ishahak M, et al. Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids. bioRxiv (2024).

The new PMOD 4.5 includes advanced tools for translational oncology research, such as dynamic segmentation tools for changing tumor volumes and organ positions, image registration across acquisitions, and detailed metadata control in the Metadata Explorer. Learn more: https://lnkd.in/dzg_H7tc #Bruker #PreclinicalImaging #Imaging #PMOD #Oncology

📢 [ASH 2024] : Our Biotech Highlights from ASH 2024 As leaders in fostering strategic partnerships to advance research and innovation in lymphoid cancers, we are thrilled to share our #biotech analysis for #ASH2024 and explore the groundbreaking innovations shaping the future of cancer research 🚀 - We identified 65 abstracts of interest in hematological malignancies, representing 56 biotechs. - These include 32 oral presentations and 33 posters, showcasing cutting-edge developments. - Notably, over half of these abstracts originate from the United States, and a quarter from China. Our team will be actively engaging with cutting-edge biotechs and exploring new collaborations that will help push the boundaries of science in the fight against hematological malignancies. Stay tuned for more updates ! #Hematology #Hematologist #clinicalresearch #ASH24 #Lymphomas #Biotech #collaborativeresearch #Myelomas #academicresearch #oncology #hematologyoncology